公开(公告)号：US20240165328A1

公开(公告)日：2024-05-23

申请号：US18422986

申请日：2024-01-25

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61M5/142 ,  G06Q30/0283 ,  G16H20/17

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61B5/4839 ,  A61M5/142 ,  G06Q30/0283 ,  G16H20/17 ,  A61M2005/14208 ,  A61M2205/52 ,  A61M2230/201

Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

公开(公告)号：US20220288300A1

公开(公告)日：2022-09-15

申请号：US17330115

申请日：2021-05-25

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY

IPC: A61M5/142 ,  G06Q30/02

Abstract: The exemplary embodiments provide medicament delivery devices that use cost functions in their control systems to determine medicament dosages. The cost function may have a medicament cost component and a performance cost component. The exemplary embodiments may use cost functions having medicament cost components that scale asymmetrically for different ranges of inputs (i.e., different candidate medicament dosages). The variance in scaling for different input ranges provides added flexibility to tailor the medicament cost component to the user and thus provide better management of medicament delivery to the user and better conformance to a performance target. The exemplary embodiments may use a cost function that has a medicament cost component (such as an insulin cost component) of zero for candidate dosages for a range of candidate dosages (e.g., below a reference dosage).

公开(公告)号：US20210244880A1

公开(公告)日：2021-08-12

申请号：US16788892

申请日：2020-02-12

Applicant: Insulet Corporation

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Trang LY ,  Yibin ZHENG ,  Connor GULLIFER ,  Kyle GROVER

IPC: A61M5/172 ,  G16H20/17

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.

公开(公告)号：US20240299660A1

公开(公告)日：2024-09-12

申请号：US18667224

申请日：2024-05-17

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Ashutosh ZADE ,  Jason O'CONNOR ,  Trang LY ,  Yibin ZHENG ,  Connor GULLIFER ,  Kyle GROVER

IPC: A61M5/172 ,  G16H20/17

CPC classification number: A61M5/1723 ,  G16H20/17 ,  A61M2202/07 ,  A61M2205/18 ,  A61M2205/3569 ,  A61M2205/50 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2205/581 ,  A61M2205/583 ,  A61M2230/201

Abstract: The exemplary embodiments attempt to identify impending hypoglycemia and/or hyperglycemia and take measures to prevent the hypoglycemia or hyperglycemia. Exemplary embodiments may provide a drug delivery system for delivering insulin and glucagon as needed by a user of the drug delivery system. The drug delivery system may deploy a control system that controls the automated delivery of insulin and glucagon to a patient by the drug delivery system. The control system seeks among other goals to avoid the user experiencing hypoglycemia or hyperglycemia. The control system may employ a clinical decision support algorithm as is described below to control delivery of insulin and glucagon to reduce the risk of hypoglycemia or hyperglycemia and to provide alerts to the user when needed. The control system assesses whether the drug delivery system can respond enough to avoid hypoglycemia or hyperglycemia and generates alerts when manual action is needed to avoid hypoglycemia or hyperglycemia.

公开(公告)号：US20230233765A1

公开(公告)日：2023-07-27

申请号：US18190678

申请日：2023-03-27

Applicant: INSULET CORPORATION

Inventor： Jason O’CONNOR ,  Joon Bok LEE ,  Trang LY ,  Todd VIENNEAU ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/28 ,  A61M5/14248 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/52 ,  A61M2205/502 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2230/63 ,  A61M2230/201

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

公开(公告)号：US20190336684A1

公开(公告)日：2019-11-07

申请号：US16404456

申请日：2019-05-06

Applicant: Insulet Corporation

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  Trang LY ,  Yibin ZHENG ,  Thomas Arnold PEYSER ,  Jennifer Lena SCHNEIDER

IPC: A61M5/172 ,  A61M5/142 ,  A61M5/145 ,  A61B5/145

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US20240399059A1

公开(公告)日：2024-12-05

申请号：US18804372

申请日：2024-08-14

Applicant: INSULET CORPORATION

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  Trang LY ,  Yibin ZHENG ,  Thomas Arnold PEYSER ,  Jennifer Lena SCHNEIDER

IPC: A61M5/172 ,  A61B5/00 ,  A61B5/145 ,  A61M5/142 ,  A61M5/145

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.

公开(公告)号：US20240252751A1

公开(公告)日：2024-08-01

申请号：US18629121

申请日：2024-04-08

Applicant: INSULET CORPORATION

Inventor： Jason O’CONNOR ,  Joon Bok LEE ,  Trang LY ,  Todd VIENNEAU ,  Yibin ZHENG ,  Ashutosh ZADE

IPC: A61M5/172 ,  A61K38/28 ,  A61M5/142

CPC classification number: A61M5/1723 ,  A61K38/28 ,  A61M5/14248 ,  A61M2005/14252 ,  A61M2205/18 ,  A61M2205/3553 ,  A61M2205/3584 ,  A61M2205/502 ,  A61M2205/52 ,  A61M2230/201 ,  A61M2230/63

Abstract: A wearable drug delivery device, techniques, and computer-readable media that provide an application that implements a diabetes treatment plan for a user are described. The drug delivery device may include a controller operable to direct operation of the wearable drug delivery device. The controller may provide a selectable activity mode of operation for the user. Operation of the drug delivery device in the activity mode of operation may reduce a likelihood of hypoglycemia during times of increased insulin sensitivity for the user and may reduce a likelihood of hyperglycemia during times of increased insulin requirements for the user. The activity mode of operation may be manually activated by the user or may be activated automatically by the controller. The controller may automatically activate the activity mode of operation based on a detected activity level of the user and/or a detected location of the user.

公开(公告)号：US20240185980A1

公开(公告)日：2024-06-06

申请号：US18440058

申请日：2024-02-13

Applicant: INSULET CORPORATION

Inventor： Joon Bok LEE ,  Yibin ZHENG ,  Jason O'CONNOR ,  Trang LY ,  Eric BENJAMIN

IPC: G16H20/17 ,  A61M5/172 ,  G16H40/67

CPC classification number: G16H20/17 ,  A61M5/1723 ,  G16H40/67 ,  A61M2205/18 ,  A61M2205/3584 ,  A61M2205/505 ,  A61M2230/201

Abstract: Disclosed are a device, a computer-readable medium, and techniques that provide an onboarding process and an adaptivity process for a drug delivery device. A processor executing an onboarding process determines whether a history of delivered insulin to a user meets certain sufficiency requirements. The onboarding process enables a processor to cause the drug delivery device to administer doses of insulin to a user according to an initial total daily insulin dose calculation that is determined based on the sufficiency of the insulin delivery history. The initial total daily insulin may be adapted according to the adaptivity process as new insulin delivery is collected. The insulin delivery history, when sufficient, may be used to set total daily insulin dosages that enable automated insulin delivery upon replacement of a drug delivery device. The adaptivity process may be implemented to modify an initial insulin delivery doses to provide adapted insulin delivery doses.

公开(公告)号：US20230181824A1

公开(公告)日：2023-06-15

申请号：US18159353

申请日：2023-01-25

Applicant: INSULET CORPORATION

Inventor： Jason O'CONNOR ,  Joon Bok LEE ,  Trang LY ,  Yibin ZHENG ,  Thomas Arnold PEYSER ,  Jennifer Lena SCHNEIDER

IPC: A61M5/172 ,  A61B5/145 ,  A61M5/142 ,  A61M5/145

CPC classification number: A61M5/1723 ,  A61B5/14532 ,  A61M5/14244 ,  A61M5/145 ,  A61B5/486

Abstract: Disclosed are a system, methods and computer-readable medium products that provide safety constraints for an insulin-delivery management program. Various examples provide safety constraints for a control algorithm-based drug delivery system that provides automatic delivery of a drug based on sensor input. Glucose measurement values may be received at regular time intervals from a sensor. A processor may predict future glucose values based on prior glucose measurement values. The safety constraints assist in safe operation of the drug delivery system during various operational scenarios. In some examples, predicted future glucose values may be used to implement safety constraints that mitigate under-delivery or over-delivery of the drug while not overly burdening the user of the drug delivery system and without sacrificing performance of the drug delivery system. Other safety constraints are also disclosed.